Updated May 2026 | BREAKING: Johnson & Johnson’s third bankruptcy attempt was rejected. J&J confirmed it will NOT appeal — opening the door for 90,000+ lawsuits to proceed to trial. A Baltimore jury awarded $1.5 billion to a single mesothelioma victim in December 2025. First payments are scheduled for November 2026. If you used Baby Powder or Shower to Shower and developed ovarian cancer — here is exactly where things stand.
Johnson & Johnson spent years trying to make these lawsuits disappear without going to trial.
They spun off a new subsidiary called LTL Management, loaded it with the talc liability, and attempted to use the bankruptcy courts to resolve all claims — past, present, and future — without individual plaintiffs ever reaching a jury. They proposed an $8 billion settlement. Then $9 billion. A federal bankruptcy judge rejected both.
In 2026, that strategy has failed — completely and finally. J&J has confirmed it will not appeal the latest bankruptcy ruling, clearing the way for 90,000+ lawsuits to move forward in the courts.
Why does this matter? Because when talc cases reach juries, juries have consistently sided with the families. A Baltimore jury awarded $1.5 billion to a single plaintiff in December 2025. A Minnesota jury awarded $65.5 million to a mother of three with mesothelioma. A California jury awarded $966 million in October 2025. Juries hear the complete story — including the internal documents showing J&J had research linking its talc products to cancer risks for decades — and they react accordingly.
The bankruptcy strategy was designed to limit J&J’s exposure before juries could deliver those verdicts. It failed. For the 90,000 families who used Baby Powder or Shower to Shower and developed ovarian cancer or mesothelioma, that failure is significant news.
What Is the Talcum Powder Lawsuit About?
The talcum powder litigation against Johnson & Johnson centers on two products that were staples of American households for generations: Johnson’s Baby Powder and Shower to Shower body powder. These products, both containing talc as their primary ingredient, were marketed for decades as safe, gentle, and beneficial for women’s personal hygiene — specifically including genital area application.
The two legal theories driving 90,000 lawsuits:
Theory 1 — Asbestos Contamination
Talc and asbestos are naturally occurring minerals that form in proximity in the earth. Industrial-scale talc mining frequently extracts talc that contains trace amounts of asbestos — a material with no safe exposure threshold and a documented causal link to mesothelioma, a rare and aggressive cancer of the lining around the lungs and other organs.
Internal J&J documents — produced in litigation and now publicly available — show company scientists and executives identified asbestos in their talc products dating to the 1970s. A critical piece of evidence emerged in 2026: The Lancet retracted a key 1977 talc safety paper that had been used for decades to support claims about talc’s safety, after it was revealed that the paper’s author was a secret Johnson & Johnson consultant at the time of publication.
The mesothelioma cases against J&J rest heavily on this asbestos contamination evidence. The December 2025 Baltimore verdict — $1.5 billion to a single plaintiff — was the largest individual verdict in J&J talc history. The December 2025 Minnesota verdict — $65.5 million — involved a mother of three with pleural mesothelioma. The October 2025 California verdict — $966 million (later reduced by the judge on punitive damages, with the family appealing) — involved a woman who had died of mesothelioma.
Theory 2 — Talc Itself Causes Ovarian Cancer
Independent of the asbestos question, epidemiological research links the application of talc-based powders to the genital area with increased ovarian cancer risk. The proposed mechanism: talc particles migrate through the reproductive tract to the ovaries, where they trigger chronic inflammation that creates conditions favorable to malignant cell growth.
Multiple studies have found associations between perineal talc use and ovarian cancer. The International Agency for Research on Cancer (IARC) — the cancer research arm of the World Health Organization — classified the perineal use of talc-based powders as “possibly carcinogenic” (Group 2B) in 2006. In 2024, the IARC moved its classification for inhaled talc to Group 1 — carcinogenic to humans.
The ovarian cancer cases form the majority of the 67,376 claims consolidated in MDL 2738 in New Jersey federal court.
The J&J Bankruptcy Strategy — And Why It Failed
To understand the current state of the litigation, you need to understand what J&J tried to do — and why courts stopped them.
The “Texas Two-Step” bankruptcy strategy:
J&J used a legal mechanism available under Texas corporate law called a divisive merger — informally called the “Texas Two-Step.” They created a new, underfunded subsidiary (LTL Management), transferred all talc liabilities to it, and immediately filed that subsidiary for bankruptcy. The goal was to use the bankruptcy court to impose a global settlement on all current and future claimants — at J&J’s preferred payment level — without the parent company ever declaring bankruptcy.
Why it was rejected:
Courts found that LTL Management was not actually in financial distress at the time of the bankruptcy filing — a requirement for bankruptcy protection. The Fourth Circuit Court of Appeals dismissed the first bankruptcy in 2023. The second attempt was dismissed in 2024. The third attempt — involving the $9 billion proposed settlement — was rejected by U.S. Bankruptcy Judge Christopher Lopez in March 2025.
The decisive moment: J&J confirmed it will NOT appeal the latest rejection. That decision — confirmed in 2026 — means the bankruptcy strategy is permanently abandoned. All 90,000+ lawsuits move forward in the civil court system.
What this means for claimants:
For families who filed during the bankruptcy proceedings, the rejection means their cases are no longer suspended. For families who haven’t yet filed, it means individual lawsuits can now proceed without the risk of being swept into a bankruptcy settlement at unfavorable terms.
The litigation is now moving rapidly. Philadelphia’s mass tort docket has scheduled bellwether trials. The MDL in New Jersey is active. And J&J — facing the prospect of repeated jury verdicts in the $1 billion+ range — has increasing incentive to negotiate individual settlements at values that reflect the actual strength of the evidence.
The Verdicts That Changed the Landscape
Jury verdicts tell the story of how the evidence actually plays in court — and in J&J talc cases, the evidence has consistently produced large plaintiff victories.
December 2025 — $1.5 Billion Single-Plaintiff Verdict (Baltimore)
A Baltimore jury awarded $1.5 billion to a single mesothelioma victim who had used J&J’s baby powder for years. This is the largest single-plaintiff verdict in J&J talc history and signals exactly what juries are willing to award when they see the complete evidence — including the internal documents showing J&J’s awareness of asbestos contamination.
December 2025 — $65.5 Million (Minnesota)
A mother of three diagnosed with pleural mesothelioma was awarded $65.5 million after a Minnesota jury found that J&J failed to adequately warn about the potential for asbestos contamination in its talc products.
December 2025 — $40 Million (California)
A California jury awarded $40 million to two ovarian cancer patients who used J&J’s talc products. This verdict addressed the ovarian cancer theory — not the mesothelioma/asbestos theory — establishing that juries will award substantial damages for the ovarian cancer claims as well.
October 2025 — $966 Million (California, reduced)
A California jury awarded $966 million to the family of a woman who died from mesothelioma after decades of Baby Powder use. The judge subsequently reduced the award by striking the punitive damages portion. The family’s attorney has indicated plans to appeal. Even the reduced award reflects the strength of the underlying case.
The pattern: These verdicts didn’t happen in isolation. They occurred across multiple states, multiple courts, and involved both mesothelioma and ovarian cancer claims. The legal theory is winning consistently.
Who Qualifies for a Talcum Powder Lawsuit?
For Ovarian Cancer Claims (MDL 2738):
You may qualify if:
- You used Johnson’s Baby Powder or Shower to Shower body powder
- Application included perineal (genital area) use — directly on the body, on underwear, or as a general body powder
- You were diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Your use of talc products predated your cancer diagnosis (usage does not need to be ongoing)
For Mesothelioma Claims:
You may qualify if:
- You used Johnson’s Baby Powder, Shower to Shower, or other talc-containing cosmetic products
- You developed pleural mesothelioma (lungs), peritoneal mesothelioma (abdomen), or pericardial mesothelioma (heart lining)
- You have no other major asbestos exposure source that would dominate the causation analysis (though talc cases can proceed even with other exposure history)
Products named in active 2026 talc lawsuits:
- Johnson’s Baby Powder (talc-based, sold in the U.S. until 2020)
- Johnson’s Baby Powder (talc-based, sold in remaining international markets until 2023)
- Shower to Shower body powder
- Some formulations of Gold Bond powder
- Clubman Pinaud Powder
- Various store-brand talcum powder products made with J&J talc supply
Other defendants in the talc litigation:
- Colgate-Palmolive — talc-containing personal care products
- Avon — talc-containing cosmetics and powder products
- Estée Lauder — certain cosmetic powder formulations
- Imerys Talc America (J&J’s talc supplier) — separate but related litigation
The usage pattern that matters most: The ovarian cancer science focuses specifically on perineal application — regular use of talc powder applied to or near the genital area. Daily or near-daily use over years or decades represents the highest exposure level. Even use patterns of 10 to 20 years of regular perineal application have supported successful lawsuits.
Settlement Value — What Talc Cases Are Worth
No standardized global settlement has been announced as of May 2026. The $9 billion proposal was rejected. The $8 billion proposal before it was rejected. J&J has confirmed it will not appeal — meaning the company will either negotiate individual or group settlements case by case, or face continued jury trials.
The verdict record provides the most reliable indicator of individual case values:
Mesothelioma cases:
| Case Category | Potential Settlement Range |
|---|---|
| Peritoneal mesothelioma (living plaintiff, strong exposure) | $1,000,000 – $10,000,000+ |
| Pleural mesothelioma (living plaintiff) | $1,000,000 – $5,000,000+ |
| Wrongful death from mesothelioma (J&J talc) | $500,000 – $5,000,000+ |
Ovarian cancer cases:
| Case Category | Potential Settlement Range |
|---|---|
| Stage III-IV ovarian cancer, heavy perineal use, strong documentation | $250,000 – $1,000,000+ |
| Stage I-II ovarian cancer, significant use history | $100,000 – $400,000 |
| Fallopian tube / peritoneal cancer | $200,000 – $800,000 |
| Wrongful death from ovarian cancer | $200,000 – $1,000,000+ |
What drives higher values:
Duration and intensity of use: Daily perineal application over 20+ years represents maximum exposure. Use patterns are documented through family testimony, purchasing records, and the simple fact that Baby Powder was a household staple in millions of American homes for decades.
Age at diagnosis: Women diagnosed with ovarian cancer in their 40s or 50s — with decades of life expectancy affected — have higher economic damages than women diagnosed later in life.
Stage of cancer at diagnosis: Stage III and IV ovarian cancer has dramatically different treatment burden and life impact than Stage I. Advanced-stage diagnoses at the time of litigation produce higher settlements.
J&J’s internal documents: The most damaging evidence in these cases — the internal research showing J&J’s awareness of asbestos in their talc — is now widely available through prior litigation discovery. In cases where plaintiffs can introduce this documentary evidence, jury verdicts escalate accordingly. The Lancet retraction of the 1977 safety paper (a paper J&J cited repeatedly in its defense) removes a key pillar of their scientific defense.
First payments timeline: According to some legal analyses, first payments for mesothelioma claims could arrive as early as November 2026, with ovarian cancer claimants beginning to receive payments in early 2027 — though these timelines depend on individual case resolution and any global settlement framework that emerges.
The Internal Documents J&J Didn’t Want You to See
The most compelling evidence in the talcum powder litigation has not come from plaintiff scientists or expert witnesses. It has come from J&J’s own files.
Documents produced in litigation and reported by Reuters, The New York Times, and other major outlets reveal:
1970s — Asbestos identified internally: J&J’s own scientists identified asbestos in their talc samples as early as the late 1960s and 1970s. Rather than ceasing use of the contaminated talc or warning consumers, the company engaged in a multiyear effort to manage the regulatory response and maintain the product’s safety image.
The IARC coordination: Internal documents show J&J monitored and sought to influence the International Agency for Research on Cancer’s classification process for talc. Communications reflect corporate concern about what a “carcinogenic” classification would mean for product sales.
The Lancet paper: The 2026 retraction of the 1977 Lancet paper — whose author was secretly on J&J’s payroll at the time of publication — eliminated one of the scientific papers J&J cited most frequently to support the claimed safety of their product. The retraction is direct evidence of the gap between J&J’s public safety assertions and what its own funded scientists were producing.
Baby powder reformulation (2020): In 2020, J&J announced it was discontinuing the sale of talc-based Baby Powder in the United States and Canada, transitioning to a cornstarch-based formula. In 2023, they discontinued the talc formula globally. The company framed this as a business decision. Plaintiffs’ attorneys point to the timing — amid mounting litigation — as an acknowledgment of the product’s risks.
The Statute of Limitations — Your Filing Deadline
In most states, you have 2 years from your ovarian cancer diagnosis (or from when you discovered or should have discovered the connection between your diagnosis and talcum powder use) to file a talcum powder lawsuit.
For wrongful death claims — where a loved one died from ovarian cancer or mesothelioma linked to talc — the statute typically begins from the date of death in most states.
| State | SOL | Notes |
|---|---|---|
| California | 2 years from discovery | Strong plaintiff track record |
| New York | 3 years | Product liability |
| Texas | 2 years | Strict |
| Florida | 4 years | Product liability rule |
| New Jersey | 2 years | MDL 2738 located here |
| Illinois | 2 years from discovery | |
| Pennsylvania | 2 years | Philadelphia mass tort docket active |
| Missouri | 5 years | Product liability — historically favorable venue |
| Georgia | 4 years | Product liability |
The discovery rule: Many women who used Baby Powder for decades were not aware of any potential cancer connection until news coverage emerged — particularly after Reuters and other outlets reported on J&J’s internal documents in 2018 and 2019. In many states, the discovery rule starts the limitations clock when you knew or should have known about the connection — not necessarily from the diagnosis date itself. If you were diagnosed years ago but only recently connected your talc use to your cancer, consult an attorney before concluding your deadline has passed.
How the Filing Process Works
Step 1 — Confirm your product use
Think back to your use of talcum powder products. When did you start? How regularly did you use them? Where on your body? How many years did you use them? This exposure history is the foundation of your claim. Family members who remember watching you use the products, store receipts, product containers (many families kept them), and prescription or medical records noting personal hygiene habits all support exposure documentation.
Step 2 — Confirm your cancer diagnosis
Your ovarian cancer or mesothelioma diagnosis must be documented in medical records. Pathology reports confirming the cancer type and stage are the central medical evidence in the case. Gather all oncology and surgical records related to your diagnosis and treatment.
Step 3 — Contact a talcum powder attorney for a free evaluation
Every attorney handling talcum powder cases works on full contingency — zero upfront cost. The evaluation is free and typically takes 20 to 30 minutes. The attorney confirms whether your exposure history and diagnosis meet current eligibility criteria.
Step 4 — File your claim
Most new talc claims against J&J are filed into MDL 2738 in New Jersey federal court or in state courts in California, Missouri, Pennsylvania, and New Jersey — jurisdictions with established talc litigation tracks. Your attorney handles all filing.
Frequently Asked Questions
I used Baby Powder but not specifically in the genital area. Do I still qualify? The strongest talc cases involve documented perineal use. If your application was limited to, for example, underarms or feet only, your case may be more challenging. However, if you applied talc to your abdomen, thighs, or underwear — even if not described as “genital” use — it may qualify depending on the facts. Discuss your specific use pattern with an attorney.
J&J stopped selling talc Baby Powder in 2020. Does that affect my claim? No. If you used talc Baby Powder before 2020 — which covers decades of regular use by millions of American women — and subsequently developed ovarian cancer, your pre-2020 use supports your claim. The 2020 discontinuation, if anything, is evidence that J&J ultimately recognized the product’s risks.
What if I used generic or store-brand talcum powder rather than Johnson’s specifically? Claims against J&J specifically require use of J&J products. Other talc manufacturers — Colgate-Palmolive, Avon, Estée Lauder, and Gold Bond — are separate defendants in related litigation. If you used another brand, you may have a claim against a different defendant. Contact an attorney who handles the full range of talc defendants.
My mother died of ovarian cancer years ago after using Baby Powder her whole life. Can we still file? Potentially yes — depending on when she died and your state’s wrongful death statute. If she died within the past 2 to 4 years (depending on state), her estate or family members may be able to file. The discovery rule also applies in some states — if you only recently connected her ovarian cancer to her Baby Powder use, the clock may have started more recently than her death date. Contact an attorney immediately to evaluate this specific situation.
Is there still time to join the talcum powder litigation? Yes. As of May 2026, attorneys are actively accepting new claims. The collapse of J&J’s bankruptcy strategy has reopened the litigation. Active bellwether trials are scheduled in Philadelphia and other jurisdictions. Cases filed now can be included in the settlement negotiations that follow those trials.
Bottom Line: 90,000 Families Were Right — And J&J Can’t Escape to Bankruptcy Court
Johnson & Johnson tried three times to use the bankruptcy system to shield itself from the full financial consequences of selling a product that its own scientists knew carried cancer risks. Three times, federal judges said no.
The verdict record — from the $1.5 billion Baltimore decision to the $40 million California ovarian cancer award to the $65.5 million Minnesota mesothelioma verdict — reflects what happens when the evidence reaches juries. The Lancet retraction of J&J’s ghost-written safety paper removes a pillar of their scientific defense. And the company’s 2020 decision to discontinue the talc product entirely speaks for itself.
If you used Johnson’s Baby Powder or Shower to Shower and developed ovarian cancer or mesothelioma — contact a talcum powder attorney today for a free case evaluation. First payments for mesothelioma cases are projected as early as November 2026. Ovarian cancer case payments may follow in early 2027. The window to file with maximum claim value is now.
This article is for informational purposes only and does not constitute legal advice. Statute of limitations and eligibility vary by state and individual facts. Consult a licensed attorney for guidance specific to your situation.
Last updated: May 2026 | Data sourced from MDL 2738 JPML docket statistics, Sokolove Law case results, LawFirm.com docket data, TorHoerman Law MDL tracker, Reuters investigative reporting on J&J internal documents, and verified court records from December 2025 verdicts